210 related articles for article (PubMed ID: 27824929)
1. Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Chen W; Kinsler VA; Macmillan D; Di WL
PLoS One; 2016; 11(11):e0166268. PubMed ID: 27824929
[TBL] [Abstract][Full Text] [Related]
2. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
3. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
4. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1).
Jendrny C; Beck-Sickinger AG
Chembiochem; 2016 Apr; 17(8):719-26. PubMed ID: 26574674
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
White GV; Edgar EV; Holmes DS; Lewell XQ; Liddle J; Polyakova O; Smith KJ; Thorpe JH; Walker AL; Wang Y; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Mar; 29(6):821-825. PubMed ID: 30691925
[TBL] [Abstract][Full Text] [Related]
7. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
8. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
[TBL] [Abstract][Full Text] [Related]
9. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
[TBL] [Abstract][Full Text] [Related]
10. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity.
Zhu Y; Underwood J; Macmillan D; Shariff L; O'Shaughnessy R; Harper JI; Pickard C; Friedmann PS; Healy E; Di WL
J Allergy Clin Immunol; 2017 Nov; 140(5):1310-1322.e5. PubMed ID: 28238749
[TBL] [Abstract][Full Text] [Related]
11. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
[TBL] [Abstract][Full Text] [Related]
12. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
13. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1.
de Veer SJ; Ukolova SS; Munro CA; Swedberg JE; Buckle AM; Harris JM
Biopolymers; 2013 Sep; 100(5):510-8. PubMed ID: 24078181
[TBL] [Abstract][Full Text] [Related]
15. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM
J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819
[TBL] [Abstract][Full Text] [Related]
16. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
Komatsu N; Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
J Invest Dermatol; 2003 Sep; 121(3):542-9. PubMed ID: 12925213
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein.
Komatsu N; Saijoh K; Otsuki N; Kishi T; Micheal IP; Obiezu CV; Borgono CA; Takehara K; Jayakumar A; Wu HK; Clayman GL; Diamandis EP
Clin Chim Acta; 2007 Feb; 377(1-2):228-36. PubMed ID: 17140555
[TBL] [Abstract][Full Text] [Related]
18. Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition.
de Veer SJ; Swedberg JE; Akcan M; Rosengren KJ; Brattsand M; Craik DJ; Harris JM
Biochem J; 2015 Jul; 469(2):243-53. PubMed ID: 25981970
[TBL] [Abstract][Full Text] [Related]
19. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
20. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Walker AL; Bingham RP; Edgar EV; Ferrie A; Holmes DS; Liddle J; Polyakova O; Rella M; Smith KJ; Thorpe JH; Wang Y; White GV; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Jun; 29(12):1454-1458. PubMed ID: 31005442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
